Literature DB >> 30775034

Circulating free tumor DNA in non-small cell lung cancer (NSCLC): clinical application and future perspectives.

Guillaume Herbreteau1, Audrey Vallée1, Sandrine Charpentier1, Nicola Normanno2, Paul Hofman3, Marc G Denis1.   

Abstract

Major advances in the treatment of non-small cell lung cancer (NSCLC) patients have been obtained during the last decade. Molecular testing of tumor samples is therefore mandatory in routine clinical practice. Tumor DNA is also present as cell-free molecules in blood, which is therefore a very useful and convenient source of tumor DNA. In this review, we discuss pre-analytical and analytical aspects of circulating tumor DNA (ctDNA) analysis. We also describe the use of ctDNA analysis in routine clinical practice, and discuss the potential use of ctDNA monitoring both to identify minimal residual disease and as a potential tool to early identify patients' response to treatment.

Entities:  

Keywords:  ALK translocation; Circulating tumor DNA (ctDNA); EGFR mutation; minimal residual disease (MRD); non-small cell lung cancer (NSCLC); tumor mutation burden (TMB)

Year:  2019        PMID： 30775034      PMCID： PMC6353745          DOI： 10.21037/jtd.2018.12.18

Source DB:  PubMed          Journal:  J Thorac Dis        ISSN： 2072-1439            Impact factor:   2.895


  11 in total

1.  Early circulating tumour DNA kinetics measured by ultra-deep next-generation sequencing during radical radiotherapy for non-small cell lung cancer: a feasibility study.

Authors:  G M Walls; L McConnell; J McAleese; P Murray; T B Lynch; K Savage; G G Hanna; D Gonzalez de Castro
Journal:  Radiat Oncol       Date:  2020-05-29       Impact factor: 3.481

2.  Longitudinal Tumor Size and Neutrophil-to-Lymphocyte Ratio Are Prognostic Biomarkers for Overall Survival in Patients With Advanced Non-Small Cell Lung Cancer Treated With Durvalumab.

Authors:  Sergey Gavrilov; Kirill Zhudenkov; Gabriel Helmlinger; James Dunyak; Kirill Peskov; Sergey Aksenov
Journal:  CPT Pharmacometrics Syst Pharmacol       Date:  2020-12-21

3.  Clinical implications of plasma circulating tumor DNA in gynecologic cancer patients.

Authors:  Lindsey M Charo; Ramez N Eskander; Ryosuke Okamura; Sandip P Patel; Mina Nikanjam; Richard B Lanman; David E Piccioni; Shumei Kato; Michael T McHale; Razelle Kurzrock
Journal:  Mol Oncol       Date:  2020-09-17       Impact factor: 6.603

Review 4.  Future Perspectives in Detecting EGFR and ALK Gene Alterations in Liquid Biopsies of Patients with NSCLC.

Authors:  Daniela Ferreira; Juliana Miranda; Paula Martins-Lopes; Filomena Adega; Raquel Chaves
Journal:  Int J Mol Sci       Date:  2021-04-07       Impact factor: 5.923

Review 5.  Early diagnosis of lung cancer: which is the optimal choice?

Authors:  Jing Ning; Tao Ge; Minlin Jiang; Keyi Jia; Lei Wang; Wei Li; Bin Chen; Yu Liu; Hao Wang; Sha Zhao; Yayi He
Journal:  Aging (Albany NY)       Date:  2021-02-11       Impact factor: 5.682

6.  Changes in Circulating Tumor DNA Reflect Clinical Benefit Across Multiple Studies of Patients With Non-Small-Cell Lung Cancer Treated With Immune Checkpoint Inhibitors.

Authors:  Diana Merino Vega; Katherine K Nishimura; Névine Zariffa; Jeffrey C Thompson; Antje Hoering; Vanessa Cilento; Adam Rosenthal; Valsamo Anagnostou; Jonathan Baden; Julia A Beaver; Aadel A Chaudhuri; Darya Chudova; Alexander D Fine; Joseph Fiore; Rachel Hodge; Darren Hodgson; Nathan Hunkapiller; Daniel M Klass; Julie Kobie; Carol Peña; Gene Pennello; Neil Peterman; Reena Philip; Katie J Quinn; David Raben; Gary L Rosner; Mark Sausen; Ayse Tezcan; Qi Xia; Jing Yi; Amanda G Young; Mark D Stewart; Erica L Carpenter; Charu Aggarwal; Jeff Allen
Journal:  JCO Precis Oncol       Date:  2022-08

7.  Clinicopathological parameters for circulating tumor DNA shedding in surgically resected non-small cell lung cancer with EGFR or KRAS mutation.

Authors:  Min-Sun Cho; Chul Hwan Park; Sungsoo Lee; Heae Surng Park
Journal:  PLoS One       Date:  2020-03-20       Impact factor: 3.240

8.  T790M mutations identified by circulating tumor DNA test in lung adenocarcinoma patients who progressed on first-line epidermal growth factor receptor-tyrosine kinase inhibitors.

Authors:  Vinodini Merinda; Gatot Soegiarto; Laksmi Wulandari
Journal:  Lung India       Date:  2020 Jan-Feb

9.  Anti-cancer treatment schedule optimization based on tumor dynamics modelling incorporating evolving resistance.

Authors:  Anyue Yin; Johan G C van Hasselt; Henk-Jan Guchelaar; Lena E Friberg; Dirk Jan A R Moes
Journal:  Sci Rep       Date:  2022-03-10       Impact factor: 4.379

10.  Clinical utility and applicability of circulating tumor DNA testing in esophageal cancer: a systematic review and meta-analysis.

Authors:  Swathikan Chidambaram; Sheraz R Markar
Journal:  Dis Esophagus       Date:  2022-02-11       Impact factor: 3.429
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.